Thema: US92532F1003
Vertex Pharma, US92532F1003
Vertex Pharma US92532F1003 zeigt die Boston Skyline am Wasser in weicher Aquarell-Malerei-Optik mit Segelbooten - Foto: THN
Vertex Pharmaceuticals stock heads into earnings as kidney drug FDA date nears
Vertex Pharmaceuticals stock enters a key earnings session as investors assess growth beyond cystic fibrosis. The kidney pipeline remains a near-term catalyst.
ad-hoc-news.de, heute 17:27 Uhr
Vertex Pharma, US92532F1003
Vertex Pharmaceuticals stock heads into Q3 results after ...
Vertex Pharmaceuticals stock enters a key earnings session on Monday. The company will release third-quarter results after US markets close.
ad-hoc-news.de, heute 12:39 Uhr
Vertex Pharma, US92532F1003
Vertex Pharmaceuticals stock faces a pivotal earnings test ...
Vertex Pharmaceuticals stock enters a closely watched earnings week. Investors are looking for evidence that new launches can broaden growth beyond cystic fibrosis.
ad-hoc-news.de, 01.11.26 17:06 Uhr
Vertex Pharma, US92532F1003
Vertex Pharmaceuticals stock eyes FDA date after RAINIER ...
Vertex Pharmaceuticals stock is heading toward a November FDA decision after positive kidney data. The regulatory date remains the next major catalyst.
ad-hoc-news.de, 30.10.26 17:08 Uhr
Vertex Pharma, US92532F1003
Vertex Pharmaceuticals stock faces key FDA test after RAINIER ...
Vertex Pharmaceuticals stock faces a key FDA decision after positive RAINIER results for its experimental kidney treatment. Longer-term data remain pending.
ad-hoc-news.de, 30.10.26 12:18 Uhr
Vertex Pharma, US92532F1003
Vertex Pharma stock gains 3.19% since report as FDA date ...
Vertex Pharma stock is being reassessed ahead of a pivotal regulatory date. RAINIER data met key endpoints, while longer-term kidney outcomes remain outstanding.
ad-hoc-news.de, 29.10.26 17:54 Uhr
Vertex Pharma, US92532F1003
Scotiabank keeps USD 558.00 target for Vertex Pharma stock ...
Revenue reached USD 3.33 billion in second-quarter 2026, up 12.50 percent. Vertex Pharma stock costs EUR 462.45 on October 27, 2026, up 0.85 percent.
ad-hoc-news.de, 27.10.26 17:50 Uhr
Vertex Pharma, US92532F1003
Vertex Pharmaceuticals advances povetacicept: what it means ...
RAINIER cut proteinuria 52.00 percent at Week 36 on October 23, 2026. Vertex Pharmaceuticals stock trades at EUR 466.08 on October 27, 2026.
ad-hoc-news.de, 27.10.26 12:06 Uhr
Vertex Pharma, US92532F1003
Benzinga cites a USD 544.00 target for Vertex Pharmaceuticals ...
Vertex reports third-quarter results November 2 after the close. Vertex Pharmaceuticals stock costs EUR 458.85 on October 26, 2026, while Nasdaq shows USD 512.00.
ad-hoc-news.de, 26.10.26 17:28 Uhr
Vertex Pharma, US92532F1003
Vertex Pharma publishes kidney results as Vertex Pharma ...
